



Unifying the care experience.

Appendix 4C





Oneview Healthcare plc

QUARTERLY ACTIVITIES REPORT

APPENDIX 4C

Quarter Ended 31 December 2023

2 January 2024



Oneview installation in Baxter's Customer Experience Center

**Baxter Partnership
Formally Launched**



**1 New Logo Added –
New Country**



**> 16,000
Contracted Beds**




ASX Release

Appendix 4C – Q4 2023 Quarterly Cash Flow Report

2 January 2024 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) (“Oneview” or “the Company”), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 December 2023 (Q4 23).

Financial Highlights

The Company had a net operating cash outflow of €0.1m, which is a decrease of €3.6m on the prior quarter and a decrease of €0.5m on the prior year corresponding quarter. The net operating cash outflow for the year totalled €7.4m, an 18% improvement on the 2022 net operating cash outflow.



Key components of the operating cash outflow in the quarter comprised:

- Receipts from customers totalled €4.3m. (A\$7.0m), an increase of 242% on the prior period and an increase of 16% on the prior year corresponding period.
- Payments in respect of staff costs of €2.2m (A\$3.6m) were lower as €385k of the development costs of the BYOD product have been capitalised in line with IFRS criteria.
- Admin and corporate costs of €859k (A\$1.4m) were in line with the prior quarter.

The Company held cash balances of €11.5m (A\$18.8m) at 31 December 2023, with zero debt.

Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees totalling €107,000 (A\$174,000).

Operational Highlights

- Oneview has signed a contract for its first customer in New Zealand. As Digital Infrastructure Delivery Partner to NTT, Oneview's solution will be installed in the Te Whatu Ora Health New Zealand New Dunedin Hospital campus.
- Oneview Patient Engagement has gone live in Catholic Health Mercy, giving patients access to their Care Team, Discharge Date, MyChart, Meal Ordering, Live TV and Movies, Calming Content and Relaxation Channels.
- Avive Health has gone live in the quarter in 123 beds across both its Brisbane and Mornington clinics.
- University of Miami Hospital's project commenced go-live across an initial 81 locations.
- The Baxter partnership was formally launched on 6th November at Baxter's Customer Experience Center in Irvine, California. The company is expecting initial purchase orders from the first Digital Door Sign customers in the coming weeks.
- Oneview's new Virtual Care API was launched. This allows customers to leverage the Oneview patient television for inpatient virtual care, including virtual observation and nursing.
- A case study featuring Children's Nebraska was published in the quarter, focusing on the success of the integration of Oneview's Digital Meal Ordering in the hospital. The hospital reported that it is now experiencing an 87% decrease in wasted and late food trays. The meal ordering call centre has reduced its call volume dramatically as there is now a 95% take-up rate of Oneview's Digital Meal Ordering. More information on this case study can be found [HERE](#).
- Work has commenced on the Children's Health Ireland ("CHI") partnership, with hardware orders underway.
- A further two net new logos are in late-stage contract negotiation, representing 2,800 new beds.
- Three of the BJC expansion sites are now live.
- The first development phase of the Bring-Your-Own-Device (BYOD) product was completed on time during the quarter. Pilot hospitals are confirmed in the US with NYU Langone and in Ireland with the Bon Secours Health System.

Outlook

Oneview enters 2024 with a number of growth drivers that should make for a very exciting year ahead.

We remain in late stage negotiations with two prominent US healthcare systems, both of whom have given us verbal confirmation that we will be contracting with them in Q1 24 to deliver two brand-name new logos to our US business.

The winning of the Baxter partnership in a highly competitive process served as a revalidation of our decision and investment strategy to migrate to the Cloud and to sustain our set-top box strategy at a time when other market participants are advocating for a Smart-TV strategy. We are confident that this partnership will yield strong results in 2024.

The market response to our market research and subsequent launch of the BYOD product, which has long been a strategic goal, has been extremely positive. We are delighted to bring NYU Langone, the #1 hospital in New York, on-board as a co-design partner for this product. Securing Bon Secours as an early pilot customer in Ireland has affirmed the potential to develop incremental market segments.

Other sales opportunities are progressing well through the pipeline. We look forward to updating the market as contracts are signed. It should be noted that enterprise contracts in healthcare are complex and when we have been selected as vendor of choice, there is no guarantee that the issuing party will ultimately procure our solution if, for example, hospital budgets remain constrained or their IT priorities change.

ESG

The Company is committed to its Environmental, Social and Governance principles and is pleased to report continued progress, as measured against the World Economic Forum universal ESG framework. Details can be found [HERE](#) on our website and will continue to be reported on a quarterly basis.

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, the Middle East and Asia to unify the care experience, in over 70 hospitals.

Enquiries:

James Fitter, CEO

Helena D'Arcy, CFO

Website : www.oneviewhealthcare.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")31st December 2023

Consolidated statement of cash flows	Current quarter €'000	Year to date (12 months) €'000
1. Cash flows from operating activities		
1.1 Receipts from customers	4,305	9,722
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,562)	(4,935)
(c) advertising and marketing	(146)	(480)
(d) leased assets	-	-
(e) staff costs	(2,232)	(9,057)
(f) administration and corporate costs	(859)	(3,291)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	4	4
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/refunded	(19)	(51)
1.7 Government grants and tax incentives	-	-
1.8 Legal claim recovery, net of costs	-	-
1.9 Other (termination costs)	-	(121)
1.10 Other (working capital movements)	387	795
1.11 Net cash from / (used in) operating activities	(122)	(7,414)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(35)	(257)
	(d) investments	-	-
	(e) intellectual property	(385)	(385)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(420)	(642)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	13,840
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(48)	(549)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(48)	13,291

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	12,170	6,410
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(122)	(7,414)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(420)	(642)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(48)	13,291
4.5	Effect of movement in exchange rates on cash held	(38)	(103)
4.6	Cash and cash equivalents at end of period	11,542	11,542

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	5,826	12,170
5.2	Call deposits	5,716	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	11,542	12,170

6.	Payments to related parties of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	107
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7. Financing facilities	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	€'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(122)
8.2 Cash and cash equivalents at quarter end (item 4.6)	11,542
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	11,542
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	95
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:2 January 2024.....

Authorised by: **BY THE BOARD**.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.